Advances in Targeted and Immunotherapy for High-Risk Cutaneous Malignancies

Area of Science:

• Dermatologic Oncology
• Immunotherapy
• Cutaneous Malignancies

Background:

• Skin cancer, including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma, is a global health concern.
• Advanced or metastatic skin cancers present significant treatment challenges with limited therapeutic options.
• Immunotherapy has emerged as a transformative approach in treating various cancers, including skin malignancies.

Purpose of the Study:

• To review recent advancements in immunotherapeutic strategies for BCC, cSCC, and melanoma.
• To synthesize current evidence and ongoing clinical trials for immunotherapy in these skin cancers.
• To explore mechanisms of immune response and potential biomarkers for predicting treatment efficacy.

Main Methods:

• Literature review of recent advancements in immunotherapy for skin cancer.
• Synthesis of current evidence from clinical trials.
• Exploration of molecular mechanisms and biomarkers related to immunotherapy response.

Main Results:

• Immunotherapy has significantly advanced the treatment landscape for BCC, cSCC, and melanoma.
• Understanding immune responsiveness and biomarkers is crucial for optimizing treatment outcomes.
• Ongoing clinical trials continue to expand the role of immunotherapy in dermatologic oncology.

Conclusions:

• Immunotherapy represents a major therapeutic innovation in dermatologic oncology.
• The integration of immunotherapy signifies a move towards precision medicine in treating skin cancers.
• Further research into immunotherapy's role, limitations, and future directions is essential for patient care.